ImmunityBio (IBRX) Capital Expenditures (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Capital Expenditures data on file, last reported at $1.8 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 545.84% YoY), and the FY2025 annual result was $3.8 million, changed N/A from the prior year.
• Capital Expenditures rose to $1.8 million in Q1 2026 per IBRX's latest filing, from $903000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $19.0 million in Q1 2023 and troughed at -$7.0 million in Q2 2023.
• A 5-year average of $3.1 million and a median of $1.3 million in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 3451.34% in 2023, then sank 160.05% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $224000.0 in 2022, then surged by 3451.34% to $8.0 million in 2023, then slumped by 160.05% to -$4.8 million in 2024, then soared by 118.9% to $903000.0 in 2025, then jumped by 96.68% to $1.8 million in 2026.
• Business Quant data shows IBRX's Capital Expenditures at $1.8 million in Q1 2026, $903000.0 in Q4 2025, and $1.6 million in Q3 2025.